Published in Clin Epigenetics on December 12, 2015
Ion channels expression and function are strongly modified in solid tumors and vascular malformations. J Transl Med (2016) 0.96
CaV channels and cancer: canonical functions indicate benefits of repurposed drugs as cancer therapeutics. Eur Biophys J (2016) 0.75
The calcium-cancer signalling nexus. Nat Rev Cancer (2017) 0.75
Prostate cancer risk regions at 8q24 and 17q24 are differentially associated with somatic TMPRSS2:ERG fusion status. Hum Mol Genet (2016) 0.75
Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science (2005) 39.06
The epigenomics of cancer. Cell (2007) 30.91
Adjusting batch effects in microarray expression data using empirical Bayes methods. Biostatistics (2006) 22.61
Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med (2003) 18.04
Conserved role of intragenic DNA methylation in regulating alternative promoters. Nature (2010) 9.81
Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia (2008) 5.92
SWAN: Subset-quantile within array normalization for illumina infinium HumanMethylation450 BeadChips. Genome Biol (2012) 4.99
Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. J Natl Cancer Inst (2008) 3.55
Common gene rearrangements in prostate cancer. J Clin Oncol (2011) 2.89
Statin use and risk of prostate cancer: results from a population-based epidemiologic study. Am J Epidemiol (2008) 2.79
Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med (2008) 2.68
Vasectomy and risk of prostate cancer. Cancer Epidemiol Biomarkers Prev (1999) 2.58
The new human tissue kallikrein gene family: structure, function, and association to disease. Endocr Rev (2001) 2.47
ETS gene fusions in prostate cancer. Nat Rev Urol (2009) 2.43
DNA methylation in glioblastoma: impact on gene expression and clinical outcome. BMC Genomics (2010) 2.32
Gene body methylation can alter gene expression and is a therapeutic target in cancer. Cancer Cell (2014) 2.28
Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol (2015) 2.20
The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis. Cancer Epidemiol Biomarkers Prev (2012) 2.13
Somatic and germline CACNA1D calcium channel mutations in aldosterone-producing adenomas and primary aldosteronism. Nat Genet (2013) 2.09
TMPRSS2-ERG gene fusion prevalence and class are significantly different in prostate cancer of Caucasian, African-American and Japanese patients. Prostate (2010) 2.05
Integration of ERG gene mapping and gene-expression profiling identifies distinct categories of human prostate cancer. BJU Int (2008) 1.88
Remodeling of channel-forming ORAI proteins determines an oncogenic switch in prostate cancer. Cancer Cell (2014) 1.82
Cav1.3 channel α1D protein is overexpressed and modulates androgen receptor transactivation in prostate cancers. Urol Oncol (2013) 1.78
Deep sequencing reveals distinct patterns of DNA methylation in prostate cancer. Genome Res (2011) 1.63
Prostate cancer. Lancet (2015) 1.58
Detection of TMPRSS2-ERG translocations in human prostate cancer by expression profiling using GeneChip Human Exon 1.0 ST arrays. J Mol Diagn (2007) 1.55
Association of TMPRSS2-ERG gene fusion with clinical characteristics and outcomes: results from a population-based study of prostate cancer. BMC Cancer (2008) 1.54
Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol (2011) 1.49
TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling. BMC Cancer (2011) 1.26
Tribbles in disease: Signaling pathways important for cellular function and neoplastic transformation. Cancer Sci (2011) 1.22
Identification of PDE4D as a proliferation promoting factor in prostate cancer using a Sleeping Beauty transposon-based somatic mutagenesis screen. Cancer Res (2009) 1.22
Genome-wide DNA methylation events in TMPRSS2-ERG fusion-negative prostate cancers implicate an EZH2-dependent mechanism with miR-26a hypermethylation. Cancer Discov (2012) 1.21
Do septins have a role in cancer? Br J Cancer (2005) 1.20
Whole-genome bisulfite sequencing of multiple individuals reveals complementary roles of promoter and gene body methylation in transcriptional regulation. Genome Biol (2014) 1.19
Identification of new differentially methylated genes that have potential functional consequences in prostate cancer. PLoS One (2012) 1.15
BMP signalling: agony and antagony in the family. Trends Cell Biol (2015) 1.09
Low-level expression of let-7a in gastric cancer and its involvement in tumorigenesis by targeting RAB40C. Carcinogenesis (2011) 1.06
Fluorescence and chromogenic in situ hybridization to detect genetic aberrations in formalin-fixed paraffin embedded material, including tissue microarrays. Nat Protoc (2008) 1.03
Molecular subtyping of primary prostate cancer reveals specific and shared target genes of different ETS rearrangements. Neoplasia (2012) 1.03
DNA methylation biomarkers as diagnostic and prognostic tools in colorectal cancer. J Mol Med (Berl) (2013) 1.02
Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer. Int J Cancer (2013) 0.95
The role of L-type voltage-gated calcium channels Cav1.2 and Cav1.3 in normal and pathological brain function. Cell Tissue Res (2014) 0.94
Suppression of 5'-nucleotidase enzymes promotes AMP-activated protein kinase (AMPK) phosphorylation and metabolism in human and mouse skeletal muscle. J Biol Chem (2011) 0.91
ETS fusion genes in prostate cancer. Endocr Relat Cancer (2014) 0.89
1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology (2010) 0.88
Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer. Epigenetics (2012) 0.88
Association of ERG and TMPRSS2-ERG with grade, stage, and prognosis of prostate cancer is dependent on their expression levels. Prostate (2015) 0.87
Phosphodiesterase 4D inhibitors limit prostate cancer growth potential. Mol Cancer Res (2014) 0.85
Regulation of T-type calcium channel expression by sodium butyrate in prostate cancer cells. Eur J Pharmacol (2014) 0.82
CACNA2D2 promotes tumorigenesis by stimulating cell proliferation and angiogenesis. Oncogene (2015) 0.82
Improved method of detecting the ERG gene rearrangement in prostate cancer using combined dual-color chromogenic and silver in situ hybridization. J Mol Diagn (2012) 0.82
Epigenomic profiling of DNA methylation in paired prostate cancer versus adjacent benign tissue. Prostate (2015) 0.80
High-resolution ERG-expression profiling on GeneChip exon 1.0 ST arrays in primary and castration-resistant prostate cancer. BJU Int (2013) 0.77
Epigenetic signature of Gleason score and prostate cancer recurrence after radical prostatectomy. Clin Epigenetics (2016) 0.75